Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

NCT00376883 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: pamidronate

Sponsor

Nordic Myeloma Study Group

Collaborators

[object Object]